MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3233/jnd-240033

Медицинская библиотека · Journal of neuromuscular diseases · 2024

Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular Dystrophy.

Cope Heidi, Fischer Ryan, Heslop Emma, McNiff Megan, Johnson Alexandra, Camino Eric, Denger Brian, Armstrong Niki, Thakrar Sejal, Bateman-House Alison, Beaverson Katherine L, Woollacott Ione O C, Phillips Dawn, Fernandez Vivian, Ganot Annie, Donisa-Dreghici Roxana, Mansfield Carol, Peay Holly

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Duchenne muscular dystrophy (DMD) is a progressive, life-limiting, neuromuscular disorder. Clinicians play an important role in informing families about therapy options, including approved gene therapies and clinical trials of unapproved therapies.

OBJECTIVE

This study aimed to understand the perspectives of clinicians about gene therapy for DMD, which has not previously been studied.

METHODS

We conducted interviews with specialist clinicians treating patients with DMD in the United States (n = 8) and United Kingdom (n = 8). Interviews were completed in 2022, before any approved gene therapies, to gain insight into barriers and facilitators to implementing gene therapy and educational needs of clinicians.

RESULTS

Most respondents expressed cautious optimism about gene therapy. Responses varied regarding potential benefits with most expecting delayed progression and duration of benefit (1 year to lifelong). Concern about anticipated risks also varied; types of anticipated risks included immunological reactions, liver toxicity, and cardiac or renal dysfunction. Clinicians generally, but not uniformly, understood that gene therapy for DMD would not be curative. Most reported needing demonstrable clinical benefit to justify treatment-related risks.

CONCLUSIONS

Our data demonstrate variability in knowledge and attitudes about gene therapy among clinicians who follow patients with DMD. As our knowledge base about DMD gene therapy grows, clinician education is vital to ensuring that accurate information is communicated to patients and families.

Для цитирования: Cope Heidi, Fischer Ryan, Heslop Emma, McNiff Megan, Johnson Alexandra, Camino Eric, Denger Brian, Armstrong Niki, Thakrar Sejal, Bateman-House Alison, Beaverson Katherine L, Woollacott Ione O C, Phillips Dawn, Fernandez Vivian, Ganot Annie, Donisa-Dreghici Roxana, Mansfield Carol, Peay Holly. Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular Dystrophy.. Journal of neuromuscular diseases. 2024. DOI: 10.3233/jnd-240033.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.